Answers are grounded in this paper and cite their sources.
This review demonstrates the use of radiopharmaceuticals for targeted therapy in specific cancers, indicating a shift towards personalized medicine.
The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is increasing. This review is focused on the examples of targeted (radio)pharmaceuticals for the imaging and therapy of neuroendocrine neoplasms (NENs), prostate cancer, and breast cancer. These examples strongly demonstrate the tendency of nuclear medicine development towards personalized medicine.
No takes yet. Share an insight, caveat, or question.
Irina Velikyan (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: